Integrated Filing — IndAS



General information about company

Scrip Code 517556
NSE Symbol PVP
MSEI Symbol NOTLISTED
ISIN INE362A01016
Name of company PVP Ventures Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 13-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 13-11-2026   18:15:00
End date and time of board meeting 13-11-2026   18:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 4,807.95 9,371.64
Other income 381.61 2,964.62
Total income 5,189.56 12,336.26
2 Expenses
(a) Cost of materials consumed 1,181.73 2,080.41
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (25.29) 48.78
(d) Employee benefit expense 979.43 1,816.27
(e) Finance costs 1,058.74 2,073.06
(f) Depreciation, depletion and amortisation expense 583.86 1,197.56
(f) Other Expenses
1 Other Expenses 1,483.86 2,908.04
Total other expenses 1,483.86 2,908.04
Total expenses 5,262.33 10,124.12
3 Total profit before exceptional items and tax (72.77) 2,212.14
4 Exceptional items 0.00 (1,085.00)
5 Total profit before tax (72.77) 1,127.14
6 Tax expense
7 Current tax 96.10 153.36
8 Deferred tax 62.86 99.20
9 Total tax expenses 158.96 252.56
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations (231.73) 874.58
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period (231.73) 874.58
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period (231.73) 874.58
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent (102.09) 1,106.13
Total profit or loss, attributable to non-controlling interests (129.64) (231.55)
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent (102.09) 1,106.13
Total comprehensive income for the period attributable to owners of parent non-controlling interests (129.64) (231.55)
21 Details of equity share capital
Paid-up equity share capital 26,040.37 26,040.37
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -0.04 0.42
Diluted earnings (loss) per share from continuing operations -0.04 0.42
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -0.04 0.42
Diluted earnings (loss) per share from continuing and discontinued operations -0.04 0.42
24 Debt equity ratio 0.600 0.600
25 Debt service coverage ratio 0.1800 0.5800
26 Interest service coverage ratio 0.300 1.00
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above Consolidated Unaudited Financial Results of Evervie Health Limited (formerly PVP Ventures Limited) ('the Holding Company') and its subsidiaries (together referred to as the Group) for the quarter and half year ended 30 September 2026 have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting (Ind AS 34) as prescribed under Section 133 of the Companies Act, 2013 and Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements Regulations), 2015, as amended, (the Listing Regulations) which were reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 13 November 2026. The Statutory Auditors of the Holding Company have carried out limited review of the results for the quarter and half year ended 30 September 2026. 2. The Holding Company had invested in 24,832; 22% Secured Redeemable Non-Convertible Debentures (NCDs) of Rs. 100,000 each issued by New Cyberabad City Projects Private Limited (NCCPL), erstwhile subsidiary and currently a related party of the Holding Company. Further, on 16 March 2015 the said investment of Rs. 24,832 Lakhs in debentures was converted to an Interest Free Secured loan against the security of Land owned by NCCPL and Land development rights available with NCCPL , repayable on 31 March 2017 which was further extended by 10 years to 31 March 2027. A further extension of 1 year until 31 March 2028 was granted vide supplementary agreement dated 07 February 2024. The outstanding principal loan amount as on 30 September 2026 is Rs. 21,843.49 Lakhs. Though NCCPL is not carrying any business activity, based on the below-mentioned factors, the Holding Company believes that while there could be a further extension of the tenor beyond the stipulated date of 31 March 2028, the amounts are fully recoverable and hence there is no necessity to create an allowance for Expected Credit Loss. i. Market value of a nearby land serving as a proxy to the land over which development rights held by NCCPL. ii. Business plans of NCCPL to monetise the land bank by developing residential and/or commercial properties. iii. Enforceable clause in the Share Purchase Agreement (SPA) which provides the first priority repayment of the loan based on the cash flows to be generated out of the project to be developed as stated in (ii) above. Additionally, the Holding Company is guaranteed 50% payout from the revenues generated in excess of the loan outstanding, out of the sale/development of the aforesaid properties. The Holding Company believes that the provisions of Section 186(1) & 188 of the Act have been complied with to the extent applicable. Further based on internal assessment/professional opinion received in this regard, the other provisions of Section 186 of the Act in respect to loans, making investments, providing guarantees and securities are not applicable to the Holding Company as it is involved in the business of providing infrastructural facilities. 3. The Holding Company was treating the aforesaid loan as deemed investment in subsidiary and hence was carrying the same at cost until 30 September 2023. Consequent to NCCPL ceasing to be a subsidiary as highlighted above, the Holding Company has carried the same at amortized cost as at 30 September 2026 in accordance with the requirements of Ind AS-109 - Financial instruments. Accordingly, the Management has carried the loan at present value by discounting the future cash flows at a rate of 8% over an estimated repayment period of 8.5 years (considering the possibility of further extension as stated above as against the balance legal tenor of 4 years). The accounting has been done in the following manner: (a) Carried as Loan under Non-Current financial assets - Interest income has been recorded under the Effective Interest Rate (EIR) method* - Amount upon initial recognition: 11,091.29; Amount carried as at 30 September 2026: 14,088.56 (b) Carried as Prepayment asset under other Non-Current Assets - Amortization would be done in proportion of revenues accruing to the Holding Company as per the SPA as stated in Note 2 (iii) above - Amount upon initial recognition: 10,752.20; Amount carried as at 30 September 2026: 10,752.20 Total amount upon initial recognition: 21,843.49 * An amount of Rs. 303.03 Lakhs and Rs. 550.63 Lakhs has been recognized as Interest Income under Other Income for the quarter and half year ended 30 September 2026 respectively. 4. During the quarter ended 30 June 2026, the Holding Company acquired additional 4,263 shares representing an additional stake of 7.99% of the paid up share capital of 7Med India Private Limited (7 Med) for a consideration of Rs. 1,926.24 Lakhs. Accordingly, the Holding Company now holds 41.23% in 7 Med. The effective date of additional investment has been considered as 1 April 2026. 5. During the quarter ended 30 September 2026, 7Med India Private Limited (7 Med), a subsidiary of the Holding Company, incorporated a subsidiary, 7 Med (South) Private Limited (7 Med South), on 03 August 2026. 7 Med subscribed to 8,500 equity shares of Rs. 10 each, representing 85% of the share capital of 7 Med South. Accordingly, 7 Med South has become a step-down subsidiary of the Holding Company and has been included in these consolidated results from the date of incorporation. 7 Med South has not commenced operations as at 30 September 2026. 6. The Holding Company had acquired Humain Healthtech Private Limited (HHT) in October 2023. HHT, in turn, has two subsidiaries, namely Noble Diagnostics Private Limited (Noble) and Apta Medical Imaging Private Limited (Apta). In accordance with Ind AS 36 - Impairment of Assets, Goodwill is not amortised but tested for impairment and whenever there is an indication of impairment, impairment loss is recognised. Accordingly, the Holding Company carried out an assessment of the estimated recoverable amount, considering the future business plans and projected cash flows of the underlying business. Based on the assessment, the recoverable amount was determined to be lower than the carrying amount due to negative net-worth of Apta. Consequently, an impairment loss of Rs. 1,085.00 Lakhs has been recorded towards Goodwill during the quarter ended 30 June 2026. Further, HHT has recognised an impairment of Goodwill of Rs. 508.85 Lakhs pertaining to its subsidiaries, Apta and Noble, which has been accounted in the consolidated results for the quarter ended 30 September 2026. The impairment losses have been presented as exceptional items in the Statement of Profit and Loss. 7. The Statement of Consolidated Assets and Liabilities as at 30 September 2026 and Statement of Consolidated Cash Flows for the half year ended 30 September 2026 are provided in Annexure 1 & 2 respectively. 8. The Group has identified reportable segments in accordance with Ind AS 108 - Operating Segments. Accordingly, two reportable segments, i.e. Real Estate and Health Care Services have been identified, the details of which are given in Segment Results - Annexure 3. 9. Subsequent to the half year ended 30 September 2026, the name of the Holding Company has been changed from PVP Ventures Limited to Evervie Health Limited with effect from 05 October 2026, pursuant to the fresh Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre. The Corporate Identity Number (CIN) of the Holding Company remains unchanged. 10. Previous period figures have been reclassified to conform to the current period classification/presentation.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 8,402.95
Capital work-in-progress 101.02
Investment property 0.00
Goodwill 14,546.06
Other intangible assets 5,266.55
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 631.23
Trade receivables, non-current 0.00
Loans, non-current 14,088.56
Other non-current financial assets
1 Other financial assets 3,242.44
Total of other non-current financial assets 3,242.44
Total non-current financial assets 17,962.23
Deferred tax assets (net) 785.46
Other non-current assets
1 Right of use assets 1,557.03
2 Income tax asset (net) 1,251.98
3 Other non-current assets 12,411.95
Total of other non-current assets 15,220.96
Total non-current assets 62,285.23
2 Current assets
Inventories 5,372.02
Current financial asset
Current investments 130.24
Trade receivables, current 3,178.96
Cash and cash equivalents 3,568.08
Bank balance other than cash and cash equivalents 867.08
Loans, current 677.86
Other current financial assets
Total of other current financial assets 417.65
Total current financial assets 8,839.87
Current tax assets (net) 0.00
Other current assets
1 Other current assets 1,573.66
Total of other current assets 1,573.66
Total current assets 15,785.55
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 78,070.78
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 26,040.37
Other equity (3,300.60)
Total equity attributable to owners of parent 22,739.77
Non controlling interest 15,935.69
Total equity 38,675.46
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 12,089.77
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Lease liabilities 1,909.85
Total of other non-current financial liabilities 1,909.85
Total non-current financial liabilities 13,999.62
Provisions, non-current 94.63
Deferred tax liabilities (net) 0.00
Deferred government grants, Non-current 0.00
Other non-current liabilities
1 Other non-current liabilities 9,945.40
Total of other non-current liabilities 9,945.40
Total non-current liabilities 24,039.65
Current liabilities
Current financial liabilities
Borrowings, current 10,957.90
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 6.42
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,632.38
Total Trade payable 2,638.80
Other current financial liabilities
1 Lease liabilities 89.61
2 Other financial liabilities 453.14
Total of other current financial liabilities 542.75
Total current financial liabilities 14,139.45
Other current liabilities 649.10
1 Other current liabilities 649.10
Total of other current liabilities 649.10
Provisions, current 185.39
Current tax liabilities (Net) 381.73
Deferred government grants, Current 0.00
Total current liabilities 15,355.67
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 39,395.32
Total equity and liabilites 78,070.78
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Real Estate 1,112.83 2,462.10
2 Health care services 3,695.12 6,909.54
Total Segment Revenue 4,807.95 9,371.64
Less: Inter segment revenue 0.00 0.00
Revenue from operations 4,807.95 9,371.64
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Real Estate 1,033.67 4,504.53
2 Health care services (47.70) (219.33)
Total Profit before tax 985.97 4,285.20
i. Finance cost 1,058.74 2,073.06
ii. Other Unallocable Expenditure net off Unallocable income 0.00 1,085.00
Profit before tax (72.77) 1,127.14
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Real Estate 55,120.08 55,120.08
2 Health care services 22,950.68 22,950.68
Total Segment Asset 78,070.76 78,070.76
Un-allocable Assets 0.00 0.00
Net Segment Asset 78,070.76 78,070.76
4 Segment Liabilities
Segment Liabilities
1 Real Estate 27,923.50 27,923.50
2 Health care services 11,471.81 11,471.81
Total Segment Liabilities 39,395.31 39,395.31
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 39,395.31 39,395.31
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 0.00 0.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,127.14
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2,073.06
Adjustments for decrease (increase) in inventories 48.78
Adjustments for decrease (increase) in trade receivables, current (564.42)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (629.19)
Adjustments for decrease (increase) in other non-current assets (16.73)
Adjustments for other financial assets, non-current 513.32
Adjustments for other financial assets, current 1,581.91
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 330.22
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (284.60)
Adjustments for increase (decrease) in other non-current liabilities 1,277.15
Adjustments for depreciation and amortisation expense 1,197.56
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 1,085.00
Adjustments for provisions, current 133.06
Adjustments for provisions, non-current (45.58)
Adjustments for other financial liabilities, current 36.07
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 71.57
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (21.12)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (2,238.14)
Other adjustments for non-cash items (613.25)
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 3,791.53
Net cash flows from (used in) operations 4,918.67
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 220.59
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 4,698.08
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 135.25
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 653.38
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 71.57
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (840.48)
Net cash flows from (used in) investing activities (1,557.54)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 1,926.24
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 1,534.37
Repayments of borrowings 2,197.11
Payments of lease liabilities 174.67
Dividends paid 0.00
Interest paid 1,905.71
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (4,669.36)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (1,528.82)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (1,528.82)
Cash and cash equivalents cash flow statement at beginning of period 5,096.90
Cash and cash equivalents cash flow statement at end of period 3,568.08





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 CNGSN & Associates LLP Yes 31-01-2029